Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.49 |
| ▸ | TUBB | P07437 | 3/20 | 0.49 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.49 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2015917 | 0.88 | KDM4E (0.58) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL5564109 | 0.86 | KMT2A (0.57) | HPGDALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL2015560 | 0.85 | KDM4E (0.55) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL25748437 | 0.85 | KDM4E (0.55) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL14654012 | 0.85 | KDM4E (0.55) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL6594500 | 0.85 | ALDH1A1 (0.55) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL7684412 | 0.84 | MEN1 (0.51) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL28265787 | 0.83 | KMT2A (0.52) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL699482 | 0.82 | FLT3 (0.60) | HPGDALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL15747095 | 0.82 | ALDH1A1 (0.52) | HPGDALDH1A1KDM4ERAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124766-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2367817-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Via Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010065310-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | VIA PHARMACEUTICALS, INC (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MADRIGAL PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
| US-6380230-B1 | FOR THERAPY OF DYSKINESIA, OBESITY, IRRITABLE BOWEL SYNDROME, DISEASES WHOSE TREATMENT REQUIRES STIMULATION OF THE CHOLECYSTOKININ CCK-A RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-04-30 | — | — | US | disclosed |
| CN-1276790-A | Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them | SANOFI SA (FR) | 2000-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145047-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | HPGD 818/4885ALDH1A1 586/4885KDM4E 2709/4885 |
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | HPGD 1247/4885ALDH1A1 630/4885KDM4E 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.